Brian Bradbury
Executive Director, Center for Observational Research
Amgen Inc
Brian D. Bradbury, DSc, is an Executive Director and Head of the Data and Analytic Center (DAC) within the Center for Observational Research (CfOR) at Amgen, Inc. As the Head of the DAC, he leads a team of epidemiologists, biostatisticians, and programmers who provide strategic and tactical support across the drug development lifecycle. The DAC has the responsibility of developing and maintaining Amgen’s RWD platform, conducting epidemiologic research on the incidence and prevalence of target clinical indications, using RWD to support RCT design, conducting feasibility analysis for post-marketing commitments, and developing Amgen’s Sentinel program, which can be used for comparative effectiveness and safety research, as well as quality of care evaluation. Brian received his DSc in Epidemiology from Boston University in 2004 and a MA in Education and Psychology from Pepperdine University in 1998. He has authored or co-authored over 70 peer-reviewed publications in the areas of pharmacoepidemiology, cancer and kidney disease epidemiology and methods for controlling confounding-by-indication in drug safety studies.
Brian D. Bradbury, DSc
1 Amgen Center Drive, MS: 24-2-A
Thousand Oaks, CA 91321
bradbury@amgen.com
(t) 805-313-4343
(c) 805-807-8623
Chertow GM, Liu J, Monda KL, Gilbertson DT, Brookhart MA, Beaubrun AC, Winkelmayer WC, Pollock A, Herzog CA, Ashfaq A, Sturmer T, Rothman KJ, Bradbury BD, Collins AJ. Epoetin alfa and Outcomes Amid Regulatory and Payment Reform. J Am Soc Nephrol 2016 (in press)
Gilbertson DT, Bradbury BD, Wetmore JB, Weinhandl ED, Monda KL, Liu J, Brookhart MA, Gustafson S, Roberts T, Collins AJ, Rothman KJ. Confounding from time-varying effects using administrative data. Pharmacoepidemiology & Drug Safety 2016; 25:269-77.
Gill K, Fink JC, Gilbertson DT, Monda KL, Muntner P, Lafayette RA, Petersen J, Chertow GM, Bradbury BD. Red blood cell transfusion, hyperkalemia, and heart failure in advanced chronic kidney disease. Pharmacoepidemiology & Drug Safety 2015; 24:654-662.
Danese MD, Halperin M, Lowe KA, Bradbury BD, Do TP, Block GA. Refining the definition of clinically important mineral and bone disorder in hemodialysis patients. Nephrol Dial Transplant 2015; 30:1336-44.
Leffell MS, Kim D, Hart J, Vega R, Petersen J, Zachary A, Rossert J, Bradbury BD. Red Blood Cell (RBC) Transfusion and Risk of Allosensitization in Patients Awaiting Primary Kidney Transplant. Transplantation 2014; 97:525-33.
Bradbury BD, Brookhart MA, Winkelmayer WC, Critchlow CW, Kilpatrick RD, Joffe MM, Feldman HI, Acquavella JF, Wang O, Rothman KJ. Evolving Statistical Methods to Facilitate Evaluation of the Causal Association between ESA Dose and Mortality in non-experimental research: Strengths and Limitations. Am J Kidney Dis 2009;54:554-560.
Bradbury BD, Do TP, Winkelmayer WC, Critchlow CW, Brookhart MA. Greater Epoetin alfa (EPO) doses and short-term mortality risk among hemodialysis patients with hemoglobin levels less than 11 g/dL. Pharmacoepidemiology & Drug Safety 2009;18:932-940.
